MA56547A - Formulations d'agents pénétrants transdermiques contenant du cannabidiol - Google Patents

Formulations d'agents pénétrants transdermiques contenant du cannabidiol

Info

Publication number
MA56547A
MA56547A MA056547A MA56547A MA56547A MA 56547 A MA56547 A MA 56547A MA 056547 A MA056547 A MA 056547A MA 56547 A MA56547 A MA 56547A MA 56547 A MA56547 A MA 56547A
Authority
MA
Morocco
Prior art keywords
formulations containing
penetrating agent
agent formulations
containing cannabidiol
transdermal penetrating
Prior art date
Application number
MA056547A
Other languages
English (en)
Inventor
Ryan Beal
Nathan Fitzsimmons
Kilmar Martinez
Audrene Mcmahon
Brandon Sand
Original Assignee
Dyve Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyve Biosciences Inc filed Critical Dyve Biosciences Inc
Publication of MA56547A publication Critical patent/MA56547A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41521,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA056547A 2019-06-18 2020-06-18 Formulations d'agents pénétrants transdermiques contenant du cannabidiol MA56547A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962863236P 2019-06-18 2019-06-18
US16/546,269 US10842758B1 (en) 2019-06-18 2019-08-20 Transdermal penetrant formulations containing cannabidiol
US16/546,270 US11026896B2 (en) 2019-06-18 2019-08-20 Transdermal penetrant formulations containing cannabidiol

Publications (1)

Publication Number Publication Date
MA56547A true MA56547A (fr) 2022-04-27

Family

ID=73461997

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056547A MA56547A (fr) 2019-06-18 2020-06-18 Formulations d'agents pénétrants transdermiques contenant du cannabidiol

Country Status (9)

Country Link
US (3) US11026896B2 (fr)
EP (1) EP3986385A1 (fr)
JP (1) JP2022537763A (fr)
KR (1) KR20220052903A (fr)
CN (1) CN115379833A (fr)
CA (1) CA3144261A1 (fr)
IL (1) IL289052A (fr)
MA (1) MA56547A (fr)
WO (1) WO2020257538A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019055880A2 (fr) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. Méthode d'administration et de traitement
CA3156257A1 (fr) 2019-10-03 2021-04-08 Starton Therapeutics, Inc. Administration transdermique de dronabinol
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
MX2022004258A (es) 2019-10-14 2022-05-26 Pike Therapeutics Inc Entrega transdermica de cannabidiol.
JP2023509352A (ja) * 2019-12-24 2023-03-08 ダイブ バイオサイエンシーズ,インク. 乾癬及び他の病気を治療するための、局所用シクロスポリン
US20220047541A1 (en) * 2020-08-17 2022-02-17 Pike Therapeutics, Inc. Pharmaceutical compositions and methods for treating parkinson's disease
US12109381B2 (en) * 2020-08-26 2024-10-08 Babak Ghalili Cannabinoid and menthol transdermal delivery systems and methods
JP2024503463A (ja) * 2021-01-13 2024-01-25 ダイブ バイオサイエンシーズ,インク. 薬剤投与用の経皮浸透製剤
WO2022187295A1 (fr) * 2021-03-02 2022-09-09 Acid Neutral Alkaline Laboratory Compositions de poloxamère et boissons
WO2022217147A1 (fr) * 2021-04-09 2022-10-13 Rosenfeld Mark J Procédés d'amélioration de la perméation cutanée de cannabinoïdes et d'amides d'acides gras
US20230059204A1 (en) * 2021-08-03 2023-02-23 Pike Therapeutics, Inc. Transdermal micro-dosing delivery of pharmaceutical agents
CN117379423A (zh) * 2021-10-22 2024-01-12 苏州澳宗生物科技有限公司 依达拉奉在自闭症谱系障碍治疗中的应用
CN116159045B (zh) * 2021-11-24 2024-03-19 四川大学华西医院 大麻二酚和/或次大麻二酚在制备局部麻醉药药效增强剂中的应用
KR20240079179A (ko) 2022-11-28 2024-06-04 아이큐어 주식회사 칸나비디올을 유효성분으로 포함하는 경피흡수 패치제
US20240299501A1 (en) * 2023-03-06 2024-09-12 Xygenyx Inc. Composition and methods of treatment using transdermal hormone supplementation
US20240350592A1 (en) * 2023-04-12 2024-10-24 Xygenyx Inc. Composition and methods of treatment using synergistically-enhanced supplementation
JP2025529608A (ja) * 2023-07-24 2025-09-09 ポビバ コーポレーション てんかんを処置する為の組成物及び方法
EP4522133B1 (fr) * 2023-07-24 2026-01-14 Poviva Corp. Compositions et méthodes de traitement de l'épilepsie
KR20250100074A (ko) 2023-12-26 2025-07-03 아이큐어 주식회사 테트라하이드로칸나비놀을 유효성분으로 포함하는 경피흡수 패치제

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8075910B2 (en) * 2004-05-20 2011-12-13 Pbm Pharmaceuticals, Inc. Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions
WO2008100977A2 (fr) * 2007-02-14 2008-08-21 N.V. Organon Agents de libération thérapeutiques
WO2011049247A1 (fr) * 2009-10-23 2011-04-28 東レ・ダウコーニング株式会社 Agent épaississant ou gélifiant pour des matières premières huileuses
US10028904B2 (en) * 2014-12-04 2018-07-24 Wisconsin Alumni Research Foundation Transdermal cannabinoid formulations
EP3915542B1 (fr) * 2014-12-23 2023-11-22 Dyve Biosciences, Inc. Formulations pour l'administration transdermique
CA2979184C (fr) * 2015-03-10 2020-09-08 Nanosphere Health Sciences, Llc Compositions et methodes a base de nanoparticules lipidiques en tant que support de cannabinoides sous des formes posologiques dosees avec precision
WO2016172698A1 (fr) * 2015-04-24 2016-10-27 BiOWiSH Technologies, Inc. Compositions et procédés pour la production de biodiesel à partir de triglycérides de rebut
EP3368084A4 (fr) * 2015-10-29 2019-07-03 Solubest Ltd Compositions pharmaceutiques pour administration par voie transmuqueuse
BR112018070140A2 (pt) * 2016-03-31 2019-02-05 Smartech Topical, Inc. sistema de distribuição
JP2020534283A (ja) * 2017-09-15 2020-11-26 アンパサンド バイオファーマシューティカルズ インコーポレイテッドAmpersand Biopharmaceuticals Inc. システインプロテアーゼのタンパク質阻害剤を介した自然転移の阻害
US20190177674A1 (en) * 2017-12-11 2019-06-13 CBD Spirits, LLC Systems, methods, and compositions of blended cannabinoid enriched beverages

Also Published As

Publication number Publication date
US10842758B1 (en) 2020-11-24
US20200397716A1 (en) 2020-12-24
CA3144261A1 (fr) 2020-12-24
KR20220052903A (ko) 2022-04-28
EP3986385A1 (fr) 2022-04-27
JP2022537763A (ja) 2022-08-29
US11026896B2 (en) 2021-06-08
US20230038462A1 (en) 2023-02-09
IL289052A (en) 2022-02-01
CN115379833A (zh) 2022-11-22
WO2020257538A1 (fr) 2020-12-24

Similar Documents

Publication Publication Date Title
MA56547A (fr) Formulations d'agents pénétrants transdermiques contenant du cannabidiol
EP4277616A4 (fr) Formulations d'agents pénétrants transdermiques pour l'administration de médicaments
EP3630145A4 (fr) Compositions pharmaceutiques comprenant du cannabidiol et du bêta-caryophyllène et leurs procédés d'utilisation
MA45290A (fr) Procédés et compositions d'agents biologiquement actifs
EP3687543A4 (fr) Agents pharmaceutiques en combinaison en tant qu'inhibiteurs de rsv
EP3256149A4 (fr) Formulations pour administration orale d'agents actifs
BR112018010234A2 (pt) spray formador de película tópica
EP4186506A4 (fr) Composition contenant un dérivé d'arylamide
MX2018013387A (es) Inhibidores de la arginasa y sus aplicaciones terapeuticas.
EP3695839A4 (fr) Agent thérapeutique pour cancers solides, qui contient un inhibiteur d'axl en tant que principe actif
EP3695830A4 (fr) Utilisation d'une composition comprenant des exosomes dérivés de cellules souches en tant que principe actif pour le renforcement et l'amélioration fonctionnelle de la barrière cutanée
EP3616696A4 (fr) Composition pharmaceutique contenant de l'enzalutamide pouvant être administrée par voie orale
EP3923730A4 (fr) Combinaisons de photosensibilisateur et d'agent chélatant destinées à être utilisées comme insecticides
EP3740553A4 (fr) Compositions d'agent conservateur antimicrobien
EP3412344A4 (fr) Composition d'agent extincteur
DOP2019000070A (es) Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos
EP3497077A4 (fr) Composés amides, compositions pharmaceutiques les contenant et leurs procédés d'utilisation
EP3500291A4 (fr) Formulations pour l'administration par voie orale d'agents actifs
EP4015042A4 (fr) Composition pharmaceutique contenant un agent antifongique en tant que principe actif
EP3313380A4 (fr) Composition pour l'administration d'agents actifs à un animal
EP3610848A4 (fr) Composition d'agent nettoyant pour la peau
PA8720601A1 (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevenciòn de trastornos psicoticos
AR110250A1 (es) Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida
EP3416626A4 (fr) Microsphères contenant des agents thérapeutiques et méthodes d'utilisation associées
EP3747469A4 (fr) Agent thérapeutique pour l'asthme contenant un inhibiteur d'il-6